Millennium Management LLC Reduces Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Millennium Management LLC decreased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 75.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 829,885 shares of the biopharmaceutical company's stock after selling 2,573,645 shares during the quarter. Millennium Management LLC owned 0.42% of Esperion Therapeutics worth $1,826,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Esperion Therapeutics by 18.6% during the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Esperion Therapeutics by 602.8% during the fourth quarter. Victory Capital Management Inc. now owns 173,083 shares of the biopharmaceutical company's stock worth $381,000 after purchasing an additional 148,456 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Esperion Therapeutics during the fourth quarter worth about $98,000. Finally, SG Americas Securities LLC grew its holdings in shares of Esperion Therapeutics by 96.6% during the fourth quarter. SG Americas Securities LLC now owns 151,482 shares of the biopharmaceutical company's stock worth $333,000 after purchasing an additional 74,433 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on ESPR. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. JMP Securities reissued a "market outperform" rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC cut their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their target price on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $6.25.

Esperion Therapeutics Stock Performance

ESPR traded up $0.06 during midday trading on Friday, hitting $1.22. The stock had a trading volume of 5,384,228 shares, compared to its average volume of 5,432,652. The company has a market cap of $241.80 million, a P/E ratio of -1.91 and a beta of 0.75. The business has a fifty day moving average of $0.96 and a 200 day moving average of $1.70. Esperion Therapeutics, Inc. has a 1 year low of $0.69 and a 1 year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $54.97 million. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.